BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
February 24, 2025 1:18 PM ESTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $23.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "Remain OW rated on BCRX shares after a solid Q424 Orladeyo print, reporting $124.2M versus the $123.5M preliminary revenue pre-released last month.... More
JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)
February 24, 2025 8:58 AM ESTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More
